ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Nurix Therapeutics Inc

Nurix Therapeutics Inc (NRIX)

16.10
-0.63
( -3.77% )
Updated: 10:22:16

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
16.10
Bid
16.06
Ask
16.10
Volume
116,976
15.71 Day's Range 16.59
4.22 52 Week Range 18.12
Market Cap
Previous Close
16.73
Open
16.51
Last Trade
75
@
16.0501
Last Trade Time
10:22:46
Financial Volume
$ 1,903,525
VWAP
16.2728
Average Volume (3m)
1,052,151
Shares Outstanding
48,894,084
Dividend Yield
-
PE Ratio
-5.60
Earnings Per Share (EPS)
-2.94
Revenue
76.99M
Net Profit
-143.95M

About Nurix Therapeutics Inc

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted pr... Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Dover, Delaware, USA
Founded
1970
Nurix Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker NRIX. The last closing price for Nurix Therapeutics was $16.73. Over the last year, Nurix Therapeutics shares have traded in a share price range of $ 4.22 to $ 18.12.

Nurix Therapeutics currently has 48,894,084 shares outstanding. The market capitalization of Nurix Therapeutics is $806.26 million. Nurix Therapeutics has a price to earnings ratio (PE ratio) of -5.60.

NRIX Latest News

Nurix Therapeutics to Host a Webcast and Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of NX-5948 Being Presented at the European Hematology Association Congress (EHA2024)

SAN FRANCISCO, June 10, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to...

Nurix Therapeutics to Participate in the Jefferies Global Healthcare Conference

SAN FRANCISCO, May 29, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.150.94043887147315.9517.2514.6985539416.26851529CS
40.714.6133853151415.3917.2814.528696250716.07833243CS
123.0122.994652406413.0918.1211.9105215115.05518216CS
267.3884.63302752298.7218.127.6594954512.95013622CS
524.4938.673557278211.6118.124.2270179611.17800447CS
156-12.8-44.290657439428.937.4254.2250635414.63536274CS
260-4.15-20.493827160520.2552.384.2246199317.44033635CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
KAVLKaival Brands Innovations Group Inc
$ 5.56
(308.82%)
27.92M
SVMHSRIVARU Holding Ltd
$ 0.385
(152.46%)
147.55M
CNSPCNS Pharmaceuticals Inc
$ 5.16
(42.54%)
215.78k
MDIAMediaco Holding Inc
$ 3.10
(31.91%)
636.48k
BIMIBIMI International Medical Inc
$ 2.19
(27.40%)
725.23k
INABIN8bio Inc
$ 1.175
(-30.06%)
1.56M
GANXGain Therapeutics Inc
$ 1.34
(-29.10%)
1.4M
NXLNexalin Technologies Inc
$ 1.01
(-26.83%)
2.29M
RZLTRezolute Inc
$ 3.90
(-24.42%)
1.77M
KYTXKyverna Therapeutics Inc
$ 11.05
(-23.48%)
1.15M
SVMHSRIVARU Holding Ltd
$ 0.385
(152.46%)
147.55M
NVDANVIDIA Corporation
$ 131.4199
(1.40%)
78.38M
LGVNLongeveron Inc
$ 3.3199
(23.42%)
44.88M
KITTNauticus Robotics Inc
$ 0.18
(12.15%)
41.23M
SQQQProShares UltraPro Short QQQ
$ 8.5399
(-0.00%)
28.99M

NRIX Discussion

View Posts
Monksdream Monksdream 2 weeks ago
NRIX more new highs up ahead
👍️0
Monksdream Monksdream 2 months ago
NRIX new 52 hi
👍️0
Monksdream Monksdream 2 months ago
NRIX new 52 hi
👍️0
Monksdream Monksdream 3 months ago
NRIX new 52 week high
👍️0
TheFinalCD TheFinalCD 2 years ago
https://ih.advfn.com/stock-market/NASDAQ/nurix-therapeutics-NRIX/stock-news/88898489/cathie-wood-doubles-down-on-these-2-strong-buy
👍️0
infamous infamous 3 years ago
what the F is wrong with this fkn stock? does it ever go up???
👍️0
Phosphene Phosphene 4 years ago
CEO: Dr. Arthur T. Sands

https://www.nurixtx.com/arthur-t-sands-m-d-ph-d/
👍️0
Phosphene Phosphene 4 years ago
Strategic partnerships with Sanofi and Gilead Sciences Inc.

https://www.nurixtx.com/research-development/strategic-partnerships/

Wellington and Baker Brothers are among Institutional Ownership and Shareholders:

https://fintel.io/so/us/nrix?__cf_chl_jschl_tk__=c9a7439112376e9f70de91c1316dfcc7e26d3519-1607403189-0-AT-0XpHMlNGWmcEzimwDKelDxLnOK6gsd8IihalGD8DcDe76KQlrWnh2Q1G3OLjfsidXSQyjVOkcCg3lXIXgKu6RIlw8DMusjRJpgnTzQP2qkahd1WSCP-5At2BI9Udfzc2vqpmlZOV3prAMIdFIh1_urJuBNq7hGlM4oSEJKFEFs8WDerUagukeDe9yBmvVg0Ne17vR8ByRaN-BlyHHxPWeTerJ_ZHoD1jnsxFYInhjhkK-XNkhe3BJ0Wzq3782kDVndNMNsb1glMkmm_NlSnc8Xbwve1nF3nGShcpgUxA-nefEgd9L74SzGXF1WftTIX4HYgwtb1BRzq82RClNfm9dr9Xb-hKp3xKKiYL4k9KfqV9OAePxDJoYgKqLUziXoA
👍️0
Phosphene Phosphene 4 years ago
Data support a planned clinical trial of NX-2127 in B-cell malignancies

http://www.globenewswire.com/news-release/2020/12/07/2140737/0/en/Nurix-Therapeutics-Presents-Preclinical-Data-at-62nd-American-Society-of-Hematology-ASH-Annual-Meeting-and-Exposition.html
👍️0

Your Recent History

Delayed Upgrade Clock